Literature DB >> 28724203

Huprine X Attenuates The Neurotoxicity Induced by Kainic Acid, Especially Brain Inflammation.

Júlia Relat1,2, Belén Pérez1,2, Pelayo Camps3, Diego Muñoz-Torrero3, Albert Badia1,2, M Victòria Clos1,2.   

Abstract

Huprine X (HX) is a synthetic anticholinesterasic compound that exerts a potent inhibitory action on acetylcholinesterase (AChE) activity, an agonist effect on cholinergic receptors, neuroprotective activity in different neurotoxicity models in vivo and in vitro and cognition enhancing effects in non-transgenic (C57BL/6) and transgenic (3xTg-AD, APPswe) mice. In this study, we assessed the ability of HX (0.8 mg/kg, 21 days) to prevent the damage induced by kainic acid (KA; 28 mg/kg) regarding apoptosis, glia reactivity and neurogenesis in mouse brain. KA administration significantly modified the levels of pAkt1, Bcl2, pGSK3β, p25/p35, increased the glial cell markers and reduced the neurogenesis process. We also observed that pre-treatment with HX significantly reduced the p25/p35 ratio and increased synaptophysin levels, which suggests a protective effect against apoptosis and an improvement of neuroplasticity. The increase in GFAP (88%) and Iba-1 (72%) induced by KA was totally prevented by HX pre-treatment, underlying a relevant anti-inflammatory action of the anticholinesterasic drug. Our findings highlight the potential of HX, in particular, and of AChEIs, in general, to treat a number of diseases that course with both cognitive deficits and chronic inflammatory processes.
© 2017 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28724203     DOI: 10.1111/bcpt.12852

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  1 in total

1.  Neuroprotective Effects of the Multitarget Agent AVCRI104P3 in Brain of Middle-Aged Mice.

Authors:  Julia Relat; Julio Come; Belen Perez; Pelayo Camps; Diego Muñoz-Torrero; Albert Badia; Lydia Gimenez-Llort; M Victòria Clos
Journal:  Int J Mol Sci       Date:  2018-09-04       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.